A novel variant in the GNE gene in a Malian patient presenting with distal myopathy

doi:10.21203/rs.3.rs-4004982/v1

Background: GNE myopathy (GM) is a rare autosomal recessive disorder caused by variants in the GNE gene and characterized by progressive distal muscle weakness and atrophy. We report a novel variant in theGNE gene causing GM in a consanguineous Malian family.

Case presentation: A 19-year-old male patient from a consanguineous family of Bambara ethnicity was seen for progressive walking difficulty and frequent falls. Neurological examination found distalmuscle weakness and atrophy and reduced tendon reflexes in four limbs. Electroneuromyography (ENMG) showed an axonal neuropathy pattern with reduced distal motor amplitudes. Charcot-Marie-Tooth (CMT) gene panel testing (Medical Neurogenetics LLC, Atlanta, GA) was negative. However, whole exome sequencing (WES) revealed a novel biallelic variant in GNE (c.1838G>A:p.Gly613Glu), segregating with the phenotype in the family. This variant is predicted to be pathogenic by several in silicoprediction tools including CADD= 29. Moreover, protein folding model showed major structural disruptions in the mutant protein.

Conclusion: This study reports a novel variant in the GNE gene causing GM, the first molecularly diagnosed in sub-Saharan Africa (SSA). It highlights the diagnosis challenges in this region and broadens the genetic spectrum of this rare disease.

Distal myopathy

GNE

novel variant

Mali

Africa

GNE myopathy (GM) (OMIM: 605820) also known as Nonaka myopathy (NM) or hereditary inclusion body myopathy (HIBM) is a rare autosomal recessive disorder caused by variants in the GNE gene [1]. Its global prevalence is estimated from 4 to 12:1.000,000 [2]. Clinically, GM typically manifests by bilateral foot drop caused by weakness of the anterior tibialis muscles with early adulthood onset. The disease progresses slowly over time to involve skeletal muscles throughout the body, with relative sparing of the quadriceps at the late stages of the disease [3–5]. Other additional symptoms including thrombocytopenia, cardiomyopathy, and neuropathic features have been previously described in patients with GM [6–8]. However, the mechanism by which GM leads to neurogenic disorders remains unknown.

Although several pathogenic variants have been reported to cause GM worldwide [7], only a few cases have been described in the North African populations [9, 10]. In this study, we report a novel variant in GNE causing GM in a Malian consanguineous family.

A 19-year-old male and his healthy relatives of Bambara ethnicity were seen for a progressive walking difficulty. He is from a consanguineous marriage (Fig. 1A) and with no remarkable past medical history. The disease started at age 17 with a gait difficulty that worsened gradually and has led to frequent falls. Neurological examination found moderate distal muscle weakness in the upper limbs and severe in the lower limbs. He had decreased tendon reflexes, bilateral flexor plantar reflexes. Muscle atrophy was noted, more marked in lower limbs involving the tibialis anterior muscles. He did not present sensory impairment as well as cardiac or auditory symptoms. Creatine Kinase (CK) level dosage was not done due to the unavailability of the patient. Nerve conduction studies showed reduced compound motor action potential (CMAP) amplitudes and none-response sensory nerves in lower limbs. Six years later, at age 25, he was seen in our clinic with severe symptoms and was wheelchair-bound.

Initially, the clinical pattern was suggestive of peripheral neuropathy, and the CMT panel testing performed in CLIA certified laboratory (Medical Neurogenetics LLC, Atlanta, GA) was negative. However, whole exome sequencing (WES) identified a novel homozygous missense variant c.1838G > A, leading to a Glycine to Glutamate change at position 613 (p.Gly613Glu) in the GNE gene. This variant was confirmed by Sanger sequencing, and the Gly613 residue is highly conserved across a wide range of species (Fig. 1B). In addition, the variant was shown to segregate with the disease status in the family (Figs. 1C and 1D). This variant is predicted to be deleterious by several in silico tools (CADD = 29) and classified as likely pathogenic (PP3, PM1, PM2) according to the American College of Medical Genetics (ACMG) criteria. More informations on the deleteriousness of the variant are provided in the Supplementary Table S1. Clinical and genetic findings are summarized in Table I.

Importantly, secondary and three-dimensional (3D) structural analyses reveal several major disruptions in the mutant protein compared to the wild-type involving helical structures (Fig. 2A and S1). In addition, hydrogen bond analysis showed that the Glycine-613 is not directly involved in bonding interaction (Fig. 2B). However, the mutant Glutamate-613 gained four hydrogen bonds with Cysteine-610 (Fig. 2C). This change is predicted to impact the physicochemical properties of the protein making it unstable while the wild-type is predicted to be stable.

The typical phenotype of GNE myopathy includes adult-onset, progressive distal muscle weakness and atrophy of the lower limbs sparing quadriceps at the late stage of the disease course [11].

Although GNE myopathy was described decades ago, its diagnosis is highly challenging solely based on clinical and electroneurographic findings. Clinically, peripheral neuropathy and GNE myopathy share similar manifestations [12]. In addition, electrophysiological characteristics of motor neuron involvement have also been described in previous studies, suggesting axonal neuropathy [13 − 15] as seen in our patient. However, no response was recorded in the bilateral sural nerve, which could be due to environmental factors. Histological studies can guide the diagnosis in some cases but are not available in Malian setting.

As the clinical and electrodiagnostic findings in our patient were mimicking peripheral neuropathy, CMT gene panel testing was done first but came negative. We took advantage of the WES technique to investigate our case and surprisingly identified a novel homozygous missense variant in the GNE gene known to cause GM. Therefore, our study further confirms that molecular diagnosis is highly contributive in discriminating these two entities.

The pathophysiology of the disease is not entirely elucidated to date, but hyposialylation of muscle glycans is thought to play an essential role [3, 16, 17]. Molecularly, GNE encodes the enzyme sialic acid epimerase, which is responsible for the last step of sialic acid biosynthesis [18–20]. Secondary structure analysis showed some major changes in the mutant protein involving the alpha helix and beta strand, predicted to impact the overall folding and physicochemical properties of the protein. Furthermore, based on InterPro domain search, this variant occurs in the ATPase, a nucleotide-binding domain that exhibits ATPase activity likely crucial to the function of GNE.

This is likely the first GNE myopathy molecularly diagnosed in the SSA found in Mali and the fourth in Africa after those reported in Tunisia and Egypt from unrelated families [9, 10].

We report a novel variant in GNE causing GNE-myopathy. It highlights the challenges of the evidence-based diagnosis in resource-limited settings for this rare condition and broadens its genetic spectrum, globally. As molecular diagnosis has become more accessible with the advent of next-generation sequencing (NGS), there is a pressing need to extend genetic studies to underexplored populations in order to uncover novel variants or genes that could further our understanding of the pathophysiology of the rare diseases and improve their management as clinical trials for several of these diseases are underway.

ACMG

American College of Medical Genetics

CADD

Combined Annotation Dependent Depletion

CK

Creatine Kinase

CMT

Charcot-Marie-Tooth disease

OMIM

Online Mendelian Inheritance in Man

WES

Whole Exome Sequencing

Ethics approval and consent to participate: This study was performed according to the guidelines of the Declaration of Helsinki and was approved by the institutional ethics committee of the Faculty of Medicine and Dentistry of the University of Sciences, Techniques and Technologies of Bamako (N°2020/129/CE/FMOS/FAPH). Written consent was obtained from all participants prior to the enrollment.

Consent for publication: The patient gave signed consent for publication.

Availability of data and materials: All the data supporting this study are available with the corresponding author.

Competing interests: Authors declare no conflict of interest.

Funding: This work is supported by grant number U01HG007044 funded by the National Institute of Neurological Disorders and Stroke and administered by the National Human Genome Research Institute under the H3Africa initiative, NINDS intramural funds NS002974

Acknowledgements: We thank the Université des Sciences, des Techniques et des Technologies de Bamako, Mali and the Centre Hospitalier Universitaire du Point "G", Bamako, Mali, the patient and his relatives for participating in this study. We are grateful to Dr. Fischbeck Kenneth Lab, Neurogenetics branch, NINDS, NIH at Bethesda, USA, for the DNA sequencing and analysis.

Authors' contributions:

Mahamadou Kotioumbé: Data acquisition, drafting the manuscript and subsequent revisions.

Alassane B. Maiga: Data acquisition, critical revisions of manuscript for intellectual content.

Salia Bamba: Data analysis and interpretation.

Lassana Cissé: Data acquisition, analysis and interpretation.

Salimata Diarra: Data acquisition and interpretation.

Salimata Diallo: Coordinated and performed clinical evaluation.

Abdoulaye Yalcouyé: Data acquisition, analysis and interpretation, critical revisions of manuscript for intellectual content.

Fousseyni Kané: Data analysis and interpretation.

Seybou H. Diallo: Clinical evaluation.

Dramane Coulibaly: Data acquisition.

Thomas Coulibaly: Clinical evaluation.

Kékouta Dembélé: Clinical evaluation

Boubacar Maiga: Data acquisition.

Cheick O. Guinto: Supervision and data acquisition.

Guida Landouré: Study design, funding acquisition, data acquisition, supervision and critical revision of the manuscript for intellectual content.

de Dios JKL, et al. Atypical presentation of GNE myopathy with asymmetric hand weakness. Neuromuscul Disord. 2014;24(12):1063–7. 10.1016/j.nmd.2014.07.006.
Jampel HD, Friedman D, Quigley H, Vitale S, Miller R. Mutation update for GNE gene variants associated with GNE myopathy. Clin Res. 2009;147(1):39–44. 10.1002/humu.22583.Mutation.
Argov Z, Yarom R. Rimmed vacuole myopathy’ sparing the quadriceps. A unique disorder in iranian jews. J Neurol Sci. 1984;64(1):33–43. 10.1016/0022-510X(84)90053-4.
Urtizberea JA, Béhin A. GNE myopathy, Medecine/Sciences, vol. 31, no. Argov 2014, pp. 20–27, 2015, 10.1051/medsci/201531s306.
Carrillo N, Malicdan MC, Huizing M. GNE Myopathy: Etiology, Diagnosis, and Therapeutic Challenges. Neurotherapeutics. 2018;000:900–14.
Izumi R, et al. GNE myopathy associated with congenital thrombocytopenia: a report of two siblings. Neuromuscul Disord. Dec. 2014;24(12):1068–72. 10.1016/J.NMD.2014.07.008.
Liu X, et al. Different electrophysiology patterns in GNE myopathy. Orphanet J Rare Dis. Dec. 2022;17(1). 10.1186/s13023-022-02355-0.
Chai Y, Bertorini TE, McGrew FA. Hereditary inclusion-body myopathy associated with cardiomyopathy: report of two siblings. Muscle Nerve. 2011;133–6. 10.1002/mus.21839.
Amouri R, Driss A, Murayama K, Kefi M, Nishino I, Hentati F. Allelic heterogeneity of GNE gene mutation in two Tunisian families with autosomal recessive inclusion body myopathy. Neuromuscul Disord. 2005;15(5):361–3. 10.1016/j.nmd.2005.01.012.
Sherif REL, Nonaka I, Nishino I, Zaitoon S. Clinical, muscle pathology and genetic features of GNE myopathy patients in Egypt: Case report. Neuromuscul Disord. 2016. https://doi.org/10.1016/j.nmd.2016.06.304.
Mullen K, Mozaffar T, Alrasheed J. GNE myopathy: History, etiology, and treatment trials. Front Neurol, 2022.
Nahari A, Curtis E, Jacob S, Abbas Y. Slowly progressive distal muscle weakness:neuropathy or myopathy?, BMJ, 12, 2019.
Grecu N et al. Mar., Motor axonal neuropathy associated with GNE mutations, Muscle Nerve, vol. 63, no. 3, pp. 396–401, 2021, 10.1002/MUS.27102.
Huang YN, et al. A case of GNE myopathy mimicking hereditary motor neuropathy. Eur J Neurol. 2020;27(11):2389–91. 10.1111/ene.14489.
Liu X, et al. Different electrophysiology patterns in GNE myopathy. Orphanet J Rare Dis. Dec. 2022;17(1). 10.1186/s13023-022-02355-0.
Carrillo N, Malicdan MC, Huizing M. GNE Myopathy: Etiology, Diagnosis, and Therapeutic Challenges. Neurotherapeutics. 2018;000:900–14.
Urtizberea JA, Béhin A. GNE myopathy, Medecine/Sciences, vol. 31, pp. 20–27, Mar. 2015, 10.1051/medsci/201531s306.
Van Wart S, Mager DE, Bednasz CJ, Huizing M, Carrillo N. Population Pharmacokinetic Model of N-acetylmannosamine (ManNAc) and N-acetylneuraminic acid (Neu5Ac) in Subjects with GNE Myopathy, Drugs in R and D, vol. 21, no. 2, pp. 189–202, 2021, 10.1007/s40268-021-00343-6.
Eisenberg I, et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet. 2001;29(1):83–7. 10.1038/ng718.
Tomimitsu H, Shimizu J, Ishikawa K, Ohkoshi N, Kanazawa I, Mizusawa H. Distal myopathy with rimmed vacuoles (DMRV): New GNE mutations and splice variant. Neurology. 2004;62(9):1607–10. 10.1212/01.WNL.0000123115.23652.6C.

Table I : Phenotypic and laboratory features of patient with GNE myopathy

Patient

Clinical data

Laboratory findings

Age

(yr)

Sex

Age of onset

(yr)

First symptom

Arm weakness

Leg weakness

Sensory loss

Nerve Conductions Studies

Genetic findings

Proximal

Distal

Proximal

Distal

II.2

19

M

17

Walking difficulty

Mild

Severe

Mild

Severe

None

Median

Ulnar

Sural

Tibial

Peroneal

GNE

c.1838G>A; p.Gly613Glu

SNAP

Amp

CMAP

Amp

CV

m/s

SNAP

Amp

CMAP

Amp

CV

m/s

SNAP

Amp

CMAP

Amp

CMAP

Amp

NP

10.1

54

11

NP

86

NR

1.8

1.7

yr = year, AMP: amplitude, SNAP: sensory nerve action potential, CMAP: compound motor action potential, CV: conduction velocity, m/s: meter per second, NP: not performed, NR: no response

No competing interests reported.

A novel variant in the GNE gene in a Malian patient presenting with distal myopathy

Status:

Version 1

Abstract

Figures

Background

Case presentation

Discussion

Conclusion

Abbreviations

Declarations

References

Tables

Additional Declarations

Supplementary Files

Status:

Version 1